JMP reiterates Oscient at market outperform

Oscient Pharmaceuticals Corp. was reiterated at a market outperform by JMP Securities analyst Adam Cutler on news that Pfizer has licensed the rights to Factive in Mexico. Oscient will receive "an up-front payment, milestones for attaining certain regulatory and sales goals as well as royalties on future sales." Other possible deals include out-licensing of Factive in Europe or Canada or a partnership for Oscient to co-promote another product. Shares of the Waltham, Mass., pharmaceutical company were up 9 cents, or 4.17%, at $2.25 on volume of 887,565 shares versus the three-month running average of 552,300 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.